+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2



Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2



Journal of Gastroenterology and Hepatology 26(1): 19-27



EZH2 is the histone H3 lysine 27 methyltransferase of polycomb-repressive complex 2. It transcriptionally silences cohorts of developmental regulators in stem/progenitors and cancer cells. EZH2 is essential in maintaining stem cell identity by globally repressing differentiation programs. Analogously, it plays a key role in oncogenesis by targeting signaling molecules that control cell differentiation. Emerging data indicate that EZH2 promotes cancer formation and progression through epigenetic activation of oncogenic signaling cascades and inhibition of pro-differentiation pathways. Genome-wide mapping analysis has been expanding the repertoire of target genes and the associated signaling pathways regulated by EZH2. Better understanding of the molecular basis of such regulations in various cancer types will help establish EZH2-mediated epigenetic silencing as a therapeutic target.

(PDF emailed within 0-6 h: $19.90)

Accession: 053014688

Download citation: RISBibTeXText

PMID: 21175789

DOI: 10.1111/j.1440-1746.2010.06447.x


Related references

Epigenetic modification in gliomas: role of the histone methyltransferase EZH2. Expert Opinion on Therapeutic Targets 18(10): 1197-1206, 2015

Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells. Molecular Endocrinology 25(11): 1892-1903, 2012

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer 78(2): 138-143, 2013

Role of the EZH2 histone methyltransferase as a therapeutic target in cancer. Pharmacology and Therapeutics 165: 26-31, 2017

Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2. Journal of Biological Chemistry 290(46): 27604-27617, 2016

Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2. Genes and Cancer 2(5): 585-592, 2011

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114(13): 2733-2743, 2009

Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells. Oncology Reports 31(2): 983-988, 2014

EZH2 Histone Methyltransferase and JMJD3 Histone Demethylase Implications in Prostate Cancer. Omics 21(12): 751-753, 2017

The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer. Omics 20(2): 123-125, 2016

The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease. Blood 122(25): 4119-4128, 2014

Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo. Oncotargets and Therapy 10: 3131-3144, 2017

Epigenetic regulation of autophagy by the methyltransferase EZH2 through an MTOR-dependent pathway. Autophagy 11(12): 2309-2322, 2016

Steroidogenic differentiation and PKA signaling are programmed by histone methyltransferase EZH2 in the adrenal cortex. Proceedings of the National Academy of Sciences of the United States of America 2018, 2018

The role of histone methyltransferase EZH2 in myelodysplastic syndromes. Expert Review of Hematology 5(2): 177-185, 2012